June 2016

New Product - Esbriet

Esbriet (pirfenidone) does not have its mechanism of action fully established as yet. Existing data indicate that pirfenidone exerts both anti‑fibrotic and anti‑inflammatory properties in animal models of inflammation and pulmonary fibrosis. Esbriet is indicated for the treatment of idiopathic pulmonary fibrosis. It is contraindicated with the concomitant use of fluvoxamine; with a history of angioedema with pirfenidone; in severe hepatic impairment or end stage liver disease and in severe renal impairment (CrCl < 30 ml/min) or end stage renal disease requiring dialysis. Esbriet is available as a hard gelatin capsule containing 267 mg of pirfenidone in bottles of 270’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au